Category Archives: Science: Biology

Cutting edge research is happening on a daily basis in our modern world, Keep up to date with our Press Release services.

Family in Washington state awarded National Outstanding Tree Farmers of the Year for Habitat Restoration Efforts


The New family gathered together on their Tree Farm in Washington

The New family of Washington, the 2019 National Outstanding Tree Farmers of the Year

“The New family embody what it means to make a positive conservation impact on our forests,” said Tom Martin, president and CEO of the American Forest Foundation, the nonprofit conservation organization that oversees the American Tree Farm System.

Today, the American Tree Farm System awarded the New family of Bellingham, Washington the National Outstanding Tree Farmers of the Year honor from among more than 70,000 certified Tree Farmers nationwide, thanks to their efforts to restore a portion of a critical watershed to help a threatened species in their state.

“The New family embody what it means to make a positive conservation impact on our forests,” said Tom Martin, president and CEO of the American Forest Foundation, the nonprofit conservation organization that oversees the American Tree Farm System. “Owning and caring for forestland in today’s age is not an easy task. A lack of resources, cumbersome processes and the rising costs of forest management are all significant barriers that can keep landowners from active forest management. Yet, the New family took on these challenges and were able to restore an important piece of habitat for the threatened salmon species. It was an incredible task, and we commend them for their passion and dedication to conservation.”

The New family, David and Dar New, and their daughter’s family, Jennifer and Jeff Parker and their sons, are owners of the Nourse Family Tree Farm in Bellingham, Washington. The 165-acre property has been in Dar’s family for three generations.

The New family began their stewardship journey with no formal forestry background or extensive financial resources, yet they knew they wanted to care for the land sustainably. Diving in head first, they hired a forester to help them write a forest management plan, took landowner education classes and spent nearly all their weekends at their property. Their hard work paid off. In 2015, the News were certified by the Washington state Tree Farm Program.

One fall, the News noticed a run of Coho salmon that had become stranded in a field. During the 1950s, one of the tributaries on the property had been ditched to create pastureland. Over time, the lower section silted in, causing the flow to disappear into the grass. Heavy rain had caused the run of salmon to end up in the field.

Being natives of the Pacific Northwest, the News were familiar with the heritage of the salmon species. Factors like habitat loss, fragmentation and development have put stress on the species, causing it to be listed as threatened or endangered in nearly three-fourths of Washington state.

The New family decided they wanted to restore the stream, knowing they would need to overcome costs, time and expertise to complete the work.

The News sought out resources to assist them, reaching out to their local conservation district. When at first they did not receive a response, they persisted, following up for almost two years before they formally began working together.

With the Snohomish Conservation District (SCD), David leveraged his engineering background to design the channel through the pasture field. The SCD helped the News apply for a Conservation Reserve Enhancement Program (CREP) easement from the U.S. Department of Agriculture to protect the area along the stream from development and harvesting, in return giving the News an annual rental fee to help cover forest management costs.

The channel was constructed in August 2016, followed by the planting of 3,000 trees along the 30 acres of stream bank to help prevent erosion and filter and clean the water. The SCD, Washington Conservation Corps crews, community volunteers, and school groups helped to complete the work.

Today, the News are able to walk the stream and watch the salmon navigate through the channel successfully. To help encourage other landowners to take on similar conservation projects, David and Dar have hosted university extension forestry events, tours, and schools and community groups to see their Tree Farm.

Across the U.S., family forest owners like the News care for the largest portion, more than one-third, of America’s forests. Their efforts are crucial to the sustainability of our country’s natural resources, such as clean water, wildlife habitat, carbon storage and a wood supply for the products Americans use every day.

The American Tree Farm System (ATFS) is an internationally-recognized education and certification program designed specifically for family forest owners. The program provides enrolled landowners with tools, community and support to keep their forests healthy. Enrolled Tree Farmers, in return, care for their land, meeting rigorous Standards of Sustainability. Collectively, there are nearly 19 million forested acres within the ATFS program nationwide.

To be considered for the Outstanding Tree Farmer of the Year award, individuals must exhibit exceptional forest stewardship to protect and improve our forest resources, and must promote forest stewardship within their communities.

The New family was selected from among this year’s Regional Outstanding Tree Farmers of the Years, which also included from the South: Stan and Suzanne Wood of Bremen, Alabama; from the Northeast: Bill and Tina Buckel of Bittinger, Maryland; and from the North Central: Mike Trail of Columbia, Missouri.

About the American Forest Foundation and American Tree Farm System:

The American Forest Foundation (AFF), a forest conservation organization, works on the ground with families, partners and elected officials to promote stewardship and keep our forests healthy. America’s family forests are vital for producing clean water and air, wildlife habitat and sustainable wood supplies. AFF’s signature program, the American Tree Farm System® is the country’s largest sustainable woodland program with a network of more than 70,000 family forest owners managing nearly 19 million acres of forestland.

East/West CEO Brings Together Biopharma Trailblazers to Discuss Key Industry Issues


News Image

“We’re honored to have distinguished industry leaders give a truly comprehensive glimpse into biotech in 2020. As our industry continues to grow, it is crucial to consider the importance of diversity in leadership, the experiences of patients, why we do what we do and how we can do it better.”

LeadingBiotech, an exclusive event series bringing together senior-level biopharma leaders through off-the-record collaboration and dialogue, today announces key issues to be discussed at its East/West CEO conference to be held January 11-12, 2020 at the Four Seasons Hotel in San Francisco.

Kicking off the week of the J.P. Morgan Healthcare Conference and other biotech industry conferences, collectively referred to as JPM week, East/West CEO brings together trailblazers in business development, diversity inclusion, patient advocacy and innovation across all areas of biotech to share insights on the state of the industry.

“We’re honored to have distinguished industry leaders give a truly comprehensive glimpse into biotech in 2020,” said Wendy Nelson, CEO of LeadingBiotech. “As our industry continues to grow, it is crucial to consider the importance of diversity in leadership, the experiences of patients, why we do what we do and how we can do it better.”

Key discussions at the conference will include:

  • Taking Stock of Where we are On Diversity in Leadership
  • The Evolving Impact of Machine Learning, Digital Health & Data
  • The Impact of M&A on Science, Innovation and the Biotech Landscape
  • A Keynote by Brian Wallach, Co-Founder of I AM ALS
  • Building a Biotech: Survival Strategies for Biotech CEOs, From Biotech CEOs


Key speakers include:

  • Brian Wallach – Co-Founder, I AM ALS
  • Sangeeta Bhatia – John J. and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science, MIT
  • Julia Owens – CEO, Millendo Therapeutics
  • Vali Papadimitrakopoulou, M.D. – Vice President, Clinical Development Leader (CDL), GPD, Pfizer
  • Onno van de Stolpe – CEO, Galapagos
  • Brandon Allgood, Ph.D. – Co-Founder & CTO, Numerate
  • Lewis Bender – CEO, Intensity Therapeutics
  • Diego Miralles – CEO, Vividion Therapeutics
  • Simeon George – CEO, SR One


See full agenda here.

Save 50% on registration through Dec. 6th exclusively for Cyber Week. Click here to register and use code CYBER for this discount.

About LeadingBiotech  

Formerly known as Boston Biotech Conferences, LeadingBiotech is an event series that brings biopharma CEOs and leaders together through intimate, off-the-record collaboration. We are working hard to create more valuable experiences to re-energize collaboration and infuse fresh ideas to better shape the future of biotech. For more information, please visit: http://www.leadingbiotech.com/.

Share article on social media or email:

Spartan Bioscience and Angiocare Partner to Bring the World’s First Rapid Precision Medicine DNA Test to Cardiac Stent Patients in Europe


DNA

We feel strongly that it will lead to better patient outcomes, lower readmission rates, and lower-cost healthcare for everyone.- Jan Willem Jongma, CEO Angiocare.

Spartan Bioscience, a world leader in precision medicine diagnostic solutions, and Angiocare, the leading distributor for medical diagnostic and interventional solutions in the Netherlands, have entered into a collaborative partnership to advance adoption of Spartan’s rapid precision medicine DNA test for cardiac stent patients and all other vascular patients who receive antiplatelet medication. Angiocare is part of Uniphar plc, the European Union’s largest integrated healthcare supply and services provider.

Over 30% of the world’s population, and 50% of Asians, carry CYP2C19 mutations. CYP2C19 is a liver enzyme that metabolizes 15% of all prescribed drugs, including antiplatelet drugs. Carrying a CYP2C19 mutation can impair drug metabolism.(1,2,3,4) Plavix® (clopidogrel), prescribed in the majority of ACS/PCI interventions worldwide, has an FDA “black box” drug label warning for poor response for CYP2C19 loss-of-function carriers.(5) For heart attack patients, most complications from poor Plavix® response occur in the first 24-48 hours after cardiac stenting.(6,7) Spartan’s rapid, portable test allows real-time, near patient determination of the patient’s genotype, aiding in determining the appropriate antiplatelet treatment.

The Spartan technology has been used in several landmark clinical studies including, POPular Genetics, a 2,500 patient, 8-year study in Europe published in the New England Journal of Medicine (NEJM), and announced at the European Society of Cardiology (ESC).(8) In addition, Spartan was used in TAILOR-PCI, a 5,300 patient, 7-year study funded by Mayo Foundation and the National Institutes of Health (NIH). TAILOR-PCI is the largest trial of genetics in cardiology and results are scheduled to be announced at the American Cardiology Association (ACC) conference in March 2020.

“Angiocare has been involved with Interventional cardiology solutions for over 16 years in the Netherlands and we are very excited to partner with Spartan to bring this innovative, non-invasive diagnostic precision medicine tool to our community of world-leading cardiologists,” said Jan Willem Jongma, CEO Angiocare. “We feel strongly that it will lead to better patient outcomes, lower readmission rates, and lower-cost healthcare for everyone.”

Paul Lem, MD. and CEO of Spartan Bioscience, said, “We are looking forward to our partnership with Angiocare. Over the last 16 years, they have established themselves as thought leaders in interventional cardiology solutions. Our collaboration with Angiocare will ultimately benefit anyone in the Netherlands who faces a life-threatening Acute Coronary Syndrome (ACS) event. Knowing what I know, I would insist on a DNA test before being prescribed an antiplatelet drug.”

About CYP2C19

The CYP2C19 enzyme metabolizes approximately 15 percent of all prescribed drugs, including important drug classes such as antiplatelet therapies, beta blockers, antidepressants, proton pump inhibitors, and anti-epileptics.(9) About 30% of Caucasians, and more than 50% of Asians and East Indians, carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(1,2,3,4) These include widely-used drugs such as Plavix®, Inderal®, Celexa®, and Losec®.

About Spartan Bioscience

Spartan Bioscience is the leader in on-demand DNA testing. (10) Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. In the same way that mainframe computers gave way to personal computers, high-throughput DNA testing systems in central labs are giving way to decentralized devices. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.

The Spartan logo is a registered trademark of Spartan Bioscience Inc.

Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals.

References

1. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.

2. Chen M et al. (2011). Atherosclerosis. 220(1):168–71.

3. Oh IY et al. (2012). Heart. 98(2):139–44.

4. Jose R et al. (2004). Fundamental & Clinical Pharmacology. 19(1): 101–105.

5. Dayoub EJ. (2018). JAMA Intern Med. 178(7): 943–950.

6. Mega JL et al. (2009). N Engl J Med. 360: 354–62.

7. Wiviott SD et al. (2007). N Engl J Med. 357: 2001–2015.

8. Claassens DMF et al. (2019). N Engl J Med. 381(17): 1621–1631.

9. dbSNP Short Genetic Variations. Reference SNP (refSNP) Cluster Report: rs12248560

10. Roberts JD et al. (2012). Lancet. 379:1705–11.

Share article on social media or email:

The Spondylitis Association of America Releases Its Axial Spondyloarthritis Treatment Recommendations for Patients and Families


SAA SpA Patient Treatment Guidelines

As a patient-centered organization, having these simplified treatment guidelines is an opportunity to empower and support the community we serve, says SAA CEO, Cassie Shafer.

SAA, in partnership with a volunteer taskforce of patients, physicians, and other experts, is proud to announce the release of its 2019 Axial Spondyloarthritis Treatment Recommendations for Patients and Families. The 2019 Clinical Practice Guidelines for physicians included 86 recommendations with updates and new guidance for the management of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) in the areas of pharmacologic and non-pharmacologic treatment options; axial SpA-related comorbidities; and disease activity assessment, imaging, and screening. SAA’s 2019 Patient Treatment Guidelines present key updates and specific treatment recommendations from the original clinical manuscript. Information is presented in simple terms to empower patients and their families to have productive conversations with their healthcare teams that will ultimately lead to more informed treatment decisions and better health outcomes. “As a patient-centered organization, having these simplified treatment guidelines is an opportunity to empower and support the community we serve,” says SAA CEO, Cassie Shafer.

The first-ever treatment guidelines for U.S. physicians treating ankylosing spondylitis and non-radiographic axial spondyloarthritis were published by the American College of Rheumatology, the Spondylitis Association of America, and the Spondyloarthritis Research and Treatment Network, and released in September of 2015. In August of 2019, the three organizations, physicians, scientists, patients, and other experts from the SpA community came together again to update these recommendations.

Both publications included “specific, actionable recommendations that clinicians could readily apply in their practices” to better serve the patient. For the more than 2.7 million Americans currently living with the disease, SAA’s 2019 Patient Treatment Guidelines serve as a helpful resource that is based on all available scientific evidence and the expertise and experiences of rheumatologists and people with axial SpA.

This document is divided into several categories: one for general information that applies to patients with axial SpA and more specific categories for patients with stable disease (no or mild signs and symptoms), or active disease (consistently moderate or severe signs and symptoms), and patients taking either non-steroidal anti-inflammatory drugs (NSAIDs), or biologic drugs. Copies of the 2019 Guidelines are available on SAA’s website at spondylitis.org.

About the Spondylitis Association of America

Since our founding in 1983, the Spondylitis Association of America has been the leading national nonprofit providing educational resources, connections, and the critical emotional support that people living with spondyloarthritis need. SAA is committed to increasing awareness of spondyloarthritis, providing information and support to patients and their families, and funding research to ultimately uncover a cure for the disease.

SAA has a wealth of information, educational materials, and resources for medical practitioners, the newly diagnosed, people who are seeking a proper diagnosis, and people who have already been diagnosed and living with the disease.

Share article on social media or email:

Hood College to Help National Park Service Fight Harmful Algae in Washington, D.C.


News Image

Drew Ferrier, director of Hood College’s Center for Coastal and Watershed Studies, said “We look forward to working with the National Park Service to find ways of controlling harmful and unsightly algal blooms in this beautiful garden.”

Hood College’s Center for Coastal and Watershed Studies has been awarded a cooperative agreement with the National Park Service to research methods of mitigating cyanobacteria blooms in the constructed lake at Constitution Gardens, a large catchment in Washington, D.C.

Potentially toxic cyanobacteria grew in high concentrations in the lake in summer 2018, and the lake has experienced other toxin-producing blooms in the past that have killed fish and produced noxious odors. Nutrients and defecation from wildlife are among the substances that enter the lake via runoff from precipitation events. That, combined with stagnant water and summer heating, create an optimal habitat for these cyanobacteria.

Hood College staff will help decide which treatment(s) is best for this lake. After a treatment is deployed, Hood will monitor water quality and algae and cyanobacteria growth at multiple locations in the lake monthly during the growing season from April through October and every other month from November through March.

Drew Ferrier, director of Hood College’s Center for Coastal and Watershed Studies, said “We look forward to working with the National Park Service to find ways of controlling harmful and unsightly algal blooms in this beautiful garden.”

Hood College is an independent, liberal arts college, offering 28 bachelor’s degrees, four pre-professional programs, 19 master’s degrees programs, two doctorates and 10 post-baccalaureate certificates. Located in historic Frederick, near Washington, D.C., Baltimore and the I-270 technology corridor, Hood gives students access to countless internships and research opportunities.

Share article on social media or email:

Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity


Catalent’s Zydis® orally disintegrating tablets

Catalent’s Zydis® orally disintegrating tablets

We believe that Catalent’s Zydis technology could give Ethicann’s pharmaceutical cannabinoids a distinct advantage in the marketplace, allowing patients to ‘self-dose’ if approved to optimize therapeutic effect.

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has entered into a partnership with Ethicann Pharmaceuticals Inc. (“Ethicann”), a Calgary-based pharmaceutical company using botanically sourced cannabinoid oils to formulate prescription drugs. The program will initially focus on using Catalent’s proven Zydis® orally disintegrating tablet technology to develop a new combination pharmaceutical-grade cannabidiol (CBD) and tetrahydrocannabinol (THC) product that, if approved, would treat patients suffering from multiple sclerosis (MS) spasticity.

One of the more common symptoms of MS, muscular spasticity causes feelings of stiffness and a wide range of involuntary muscle spasms in patients. Ethicann will investigate the new Zydis product for the treatment of patients who have shown inadequate response to other symptomatic treatments or who have difficulty tolerating the side effects of other treatments.

Ethicann currently intends to seek approval from the U.S. FDA for this developmental therapeutic product under the “505(b)(2)” regulatory pathway and, for Canada, an expedited approval pathway not requiring extended clinical studies.

Ethicann plans to work with Catalent to leverage the Zydis delivery platform for other cannabinoid-based products as they approach clinical studies, including a combination of THC and CBD for the treatment of chemotherapy-induced nausea and vomiting (CINV), chronic pain, post-traumatic stress disorder (PTSD), and opioid mitigation.

Commenting on the partnership, Jonathan Arnold, President of Catalent’s Oral and Specialty Delivery business unit, stated, “CBDs and THCs are notoriously insoluble and poorly bioavailable so a Zydis sublingual dosage form provides a drug delivery solution by avoiding first pass metabolism.” He added, “Catalent has a proven track record in working with partners to bring new therapies to market quickly and we look forward to collaborating with Ethicann as it prepares for these important studies.”

Bruce Mackler, Ph.D., J.D., Ethicann’s President continued, “We believe that Catalent’s Zydis technology could give Ethicann’s pharmaceutical cannabinoids a distinct advantage in the marketplace, allowing patients to ‘self-dose’ if approved to optimize therapeutic effect.”

Catalent’s 250,000 sq. ft. site in Swindon, U.K. houses the company’s Zydis development and manufacturing operation, which produces over one billion tablets annually and employs more than 600 people. The company recently began work on extending the facility to allow for the commercialization of its proprietary Zydis Ultra® technology, which allows an increased drug load and taste masking to be incorporated into each dose.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.

About Ethicann

Ethicann Pharmaceuticals develops cannabinoid-based ethical pharmaceuticals for treatment of a variety of disorders. Headquartered in Calgary, AB Canada, Ethicann’s pipeline includes treatments for MS spasticity, chemotherapy-induced nausea and vomiting, chronic pain, post-traumatic stress disorder (PTSD) and opioid mitigation. Ethicann’s competitive advantages include botanically-sourced cannabinoids and unique drug delivery systems.

Share article on social media or email:

VGXI Selects BE&K as Design-Build Partner for New Manufacturing Facility


VGXI New Facility Rendering

The choice of BE&K is based on their strong reputation and extensive experience serving advanced manufacturing businesses, especially within the biotech industry. We look forward to a productive partnership as we move forward with the first phase of our company’s facility expansion

VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services company BE&K Building Group as Design-Build Partner for the initial phase of its new manufacturing site. The planned 240,000-square-foot facility will include expanded manufacturing capabilities and multiple flexible production suites to support both DNA and RNA-based biopharmaceuticals at all phases of development through commercial supply. Design of the first phase of the site is already underway, with projected completion of the initial facility within 2 to 3 years.

“The choice of BE&K is based on their strong reputation and extensive experience serving advanced manufacturing businesses, especially within the biotech industry,” stated VGXI CEO Young Park. “We look forward to a productive partnership as we move forward with the first phase of our company’s facility expansion.”

According to market reports, the gene therapy industry is rapidly gaining speed as recent approvals pave the way for a whole new class of medicines. A driving factor for both site selection and building design is available capacity to support VGXI’s continued, future expansions to meet growing industry demand. VGXI has identified and selected a suitable location for the construction project, with approval granted in November for a $1.2 million incentive during a special council meeting by the City of Conroe.

ABOUT VGXI, INC.

VGXI, Inc. is a leading provider of manufacturing and development services for DNA vaccines and gene therapies. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CDMO of GeneOne Life Science, Inc. To learn more or request a quote, visit http://www.vgxii.com.

ABOUT GENEONE LIFE SCIENCE

GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) is an international DNA vaccine and product developer, and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines and products to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne’s wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. For more information, visit http://www.genels.com/en.

ABOUT BE&K BUILDING GROUP

BE&K Building Group is an integrated construction services company serving pharmaceutical + biotechnology, advanced manufacturing + distribution, healthcare, and additional select commercial markets for more than 50 years. The company provides services nationwide through operations in Houston, Chicago, and the Carolinas. A full range of services is offered including construction management, design-build, preconstruction, programming + master planning, and client advisory + consulting. Additional information is available at http://www.bekbg.com.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS

Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Share article on social media or email:

ASGCT Resources on Blood Cancers and CAR T-Cell Therapy Conclude Patient Education Releases for 2019


Learn how CAR T-cell therapy can modify a person’s T cells in order to recognize and kill cancer cells.

The American Society of Gene & Cell Therapy (ASGCT) is releasing the final of the second group of disease-specific resources from its Patient Education program, a new initiative in 2019. The final new resources focus on using CAR T-cell therapy to treat blood cancers.

Beginning in October, ASGCT has released new resources weekly on the Patient Education portal. Designed by ASGCT committee volunteers in coordination with patient advocacy groups, the patient-centered portal aims to educate and inform patients, families, and the public on the status and promise of gene and cell therapies.

The Patient Education resources on blood cancers and CAR T-cell therapy are now available on ASGCT.org. CAR T-cell therapy is a treatment approach that modifies T cells, a type of immune system cell, so that they have the ability to recognize and kill cancer cells. CART T-cell therapy is currently approved by the FDA to treat types of lymphoma and leukemia, which are cancers of the blood cells.

To learn about any of the diseases profiled during the second round, visit these pages:


About ASGCT

The American Society of Gene & Cell Therapy is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals with interest in gene and cell therapy. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.

Share article on social media or email:

Agenus Implements Genedata End-to-End Biologics Workflow Platform for Immunotherapy R&D


Genedata

Genedata Biologics was the clear choice as a backbone system to support the full diversity of our complex and rapidly evolving antibody discovery processes in the US and the UK.

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Agenus, a clinical-stage immuno-oncology company developing therapies to fight cancer, has chosen Genedata Biologics® as a part of their antibody R&D workflow platform. Agenus will use the platform to support immunotherapy and vaccine pipeline programs across their global organization.

“Genedata Biologics was the clear choice as a backbone system to support the full diversity of our complex and rapidly evolving antibody discovery processes in the US and the UK,” said Dennis Underwood, Ph.D., VP Molecular and Information Systems at Agenus. The platform helps streamline Agenus’s growing pipeline of checkpoint-inhibitor candidates and simultaneously supports screening, engineering, expression, purification, and analytics processes for proteins and antibodies, including bispecifics and other innovative next-generation molecules.

Agenus scientists have set path-breaking records delivering new discoveries to the clinic in the past three years. The Genedata Biologics technology, in conjunction with Agenus’s Intelligent (Re)search (AIR) platform, will further augment Agenus scientists’ ability to capture, process, and interpret all large-molecule R&D data and is an important component of the Agenus collaborative data and information platform. Molecule, sample, assay and analytics data, including developability and manufacturability data, are shared between different project teams and sites. This enables systematic and transparent decision-making when selecting therapeutic candidates to be progressed through the clinical development pipeline.

“We are excited that Agenus, a leading company developing unique immune therapies for patients with cancer, has chosen Genedata Biologics as core infrastructure to support their biotherapeutics discovery processes,” said Othmar Pfannes, Ph.D., CEO of Genedata. “This collaboration also demonstrates that innovative, fast-paced biopharma companies can benefit from an integrated data capture and workflow management system. We look forward to a long and productive partnership helping Agenus increase the efficiency of their biologics discovery and development processes.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.

http://www.genedata.com

LinkedIn | Twitter | YouTube

Contact

Miles Fisher-Pollard

Genedata

Public Relations

Phone: +41 61 511 85 61

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:



Elastochem Launches Canada’s First Polyurethane, Two-Component, Spray-Applied Waterproofing Membrane For Below-Grade Foundations


In today’s market, new building materials have to do more than perform.

Elastochem Specialty Chemicals Inc., a leading Canadian manufacturer of spray polyurethane materials, announced on Thursday the certification of Hygrothane, Canada’s first spray-applied, two-component, polyurethane-based waterproofing membrane. Hygrothane is a complete, polyurea-based membrane system that is applied at high pressure. When cured, it forms a seamless, monolithic waterproofing membrane on below-grade concrete foundation walls. The durable and flexible formula is made with 100% solids, can be applied at below-freezing temperatures and contains no VOCs.

Foundation waterproofing can be an extremely time-consuming and challenging procedure. Traditional systems, such as peel and stick and sheet membranes pose the risk of inconsistent seams that may lead to subsequent water build-up. Other drawbacks include the need for additional coatings that require further application and curing time. Meanwhile, other liquid-applied formulas are primarily water-based, which means that they face limitations at below-freezing weather conditions.

Hygrothane solves these problems by offering a smooth, one-step application that eliminates the use of primers, long curing times, and delays. It performs in below-freezing temperatures, which makes it ideal for all-season construction and challenging northern locations. The spray-applied liquid cures to form a solid membrane, eliminating seams or joints, which addresses the most common areas where waterproofing tends to fail. The buildable formula can be applied on irregular surfaces and is ideal for applications where complete coverage with a sheet membrane is unlikely. Foundations sprayed with Hygrothane can be backfilled in under one hour post-application.

“In today’s market, new building materials have to do more than perform,” said John Volk, General Manager of Elastochem, “They also have to speak to the pressing needs of the time-strapped builder and contractor. Hygrothane is a one-step system that can adapt to Canada’s varying climate and will help reduce construction schedules.”

Hygrothane is listed by the NRC under CCMC listing 14144-R.

###

ABOUT CCMC:

The Canadian Construction Materials Centre (CCMC), which operates within the National Research Council of Canada (NRC), provides a national evaluation service for all types of innovative building construction materials, products, systems and services. The CCMC is a federal body that determines what building materials meet the high standards to be approved federally. CCMC-evaluated products are used in commercial and residential buildings.

ABOUT ELASTOCHEM:

Elastochem is a Canadian leader of high-performing polyurethane and epoxy-based products, producing spray foam insulation, coatings, sealants, adhesives and primers. Elastochem focuses strongly on innovating to meet evolving industry demands and developing energy-efficient products to serve a wide range of industries.

MEDIA CONTACT:

Corrine Tam

ctam@elastochem.com

Elastochem Specialty Chemicals Inc.

Share article on social media or email: